Asterias Biotherapeutics to Begin Dose Escalation in SCiStar Phase 1/2a Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
October 20, 2015 at 06:39 AM EDT
Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced that its Data Monitoring Committee has reviewed the initial safety data ...
